SCI
ALNY icon

S&CO Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

S&CO Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Hold
7,400
– – 0.13% 112
2026
Q1 		$2.45M Sell
7,400
-800
-10% -$272K 0.15% 105
2025
Q4 		$3.26M Hold
8,200
– – 0.2% 91
2025
Q3 		$3.74M Sell
8,200
-1,850
-18% -$753K 0.23% 87
2025
Q2 		$3.28M Hold
10,050
– – 0.21% 90
2025
Q1 		$2.71M Buy
10,050
+4,300
+75% +$1.11M 0.18% 100
2024
Q4 		$1.35M Hold
5,750
– – 0.09% 124
2024
Q3 		$1.58M Hold
5,750
– – 0.1% 125
2024
Q2 		$1.4M Hold
5,750
– – 0.1% 127
2024
Q1 		$859K Buy
+5,750
New +$959K 0.06% 142

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

S&CO Inc's ALNY Position: Q2 2026 in Review

S&CO Inc held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 7,400 shares worth $2.23M. The position accounts for 0.13% of the portfolio, ranked #112.

S&CO Inc first reported a position in ALNY in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.74M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • S&CO Inc held 7,400 shares of Alnylam Pharmaceuticals worth $2.23M as of Q2 2026.
  • S&CO Inc left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.13% of S&CO Inc's portfolio in Q2 2026, its #112 holding.
  • S&CO Inc first reported a position in Alnylam Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • S&CO Inc's Alnylam Pharmaceuticals position peaked at $3.74M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on S&CO Inc's 13F filing for Q2 2026, filed 6 Aug 2026.